News | May 26, 2022
Strides Pharma Science Q4FY22 consolidated PAT at Rs. 29.21 Cr
The company has posted net loss of Rs. 460.21 crores for the Financial Year ended March 31, 2022.
The company has posted net loss of Rs. 460.21 crores for the Financial Year ended March 31, 2022.
Five patient-first principles to provide the highest standard of healthcare
By 2025, the company plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry
The two-year agreement will grant Lonza access to IBF's prominent network and allow IBF to benefit from Lonza's manufacturing expertise and knowledge in its due diligence review of potential targets
The new IGX-Track App adds seamless analysis of antibody panning campaigns to the IGX Platform
New block enhances the company's global capabilities in Oral Solid Dosage (OSD) Forms, increasing total plant capacity to 4.5 billion doses
Pfizer calls upon global health leaders and organizations to join the Accord, bringing their expertise and resources to close the health equity gap
This lawsuit has been filed in the Pennsylvania Federal Court. NATCO and its marketing partner Mylan
Belmore, the brand name of Bempedoic acid, is a novel drug for the treatment of high LDL-cholesterol.
The tablets have an estimated market size of US $ 548 million for twelve months ending December 2021 according to IQVIA
Subscribe To Our Newsletter & Stay Updated
